Abstract
Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance
Since pembrolizumab (Keytruda®) was approved for advanced melanoma in September 2014, multiple PD-1 blockade agents have been explored in other malignancies. Emerging clinical data has demonstrated durable clinical activity and safety of PD-1/L1 blockade agents in diverse cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma, and head and neck cancer. Thus, PD-1/L1 blockade agents have led to a paradigm shift in cancer therapy. In this review, current indications of PD-1 blockade agents in advanced solid malignancies will be discussed.
Author(s): Dae Won Kim, Marc Uemura and Adi Diab
Abstract | Full-Text | PDF
Share this
30+ Million Readerbase
Abstracted/Indexed in
- Google Scholar
- Genamics JournalSeek
- China National Knowledge Infrastructure (CNKI)
- Directory of Research Journal Indexing (DRJI)
- WorldCat
- Secret Search Engine Labs
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences